




FACT SHEET JULY 2007

CORPORATE OVERVIEW

Sorin Group is the largest cardiovascular company in Europe. Listed on the Italian Stock Exchange, Sorin is a world leader in the development of medical technologies for cardiac surgery and offers innovative therapies for cardiac rhythm dysfunctions, interventional cardiology and the treatment of chronic kidney diseases.

For over 40 years, the world's medical community has known and appreciated Sorin Group brands: Bellco-Soludia, CarboMedics, COBE Cardiovascular, Dideco, ELA Medical, Mitroflow, Sorin Biomedica, Stöckert.

THERAPEUTIC AREAS

- **Cardiac Surgery (CS)** is the Group's main business area and produces mechanical and tissue cardiac valves, adult and paediatric oxygenators, extracorporeal blood circulation systems, annuloplasty rings and autologous blood transfusion systems.
- **Cardiac Rhythm Management (CRM)** includes the manufacturing of implantable defibrillators, pacemakers and systems to treat heart failure (CRT-D, CRT-P) as well as holter monitors.
- **Vascular Therapy (VT)** includes coronary stents, drug-eluting and non-drug-eluting, based on the exclusive Carbofilm™ coating technology.
- **Renal Care (RC)** comprises disposables and systems used in haemodialysis for the treatment of chronic renal diseases.

MANAGEMENT TEAM

Umberto Rosa, Chairman

André-Michel Ballester, President Cardiac Rhythm Management

Eric Beard, President Corporate International

Marco Chiadò Piat, VP Corporate Development

Stefano Di Lullo, President CVH Division

Demetrio Mauro, VP Chief Financial Officer

Aldo Lombardi, VP Chief Internal Audit

Luca Magni, VP Human Resources Worldwide

Brian Sheridan, VP Corporate Legal Affairs

Luciano Soldi, General Counsel

Franco Vallana, President R&D and CVH Operations; CSO

GLOBAL REACH

With a global sales network that covers more than 5,000 hospitals in 80 countries, the Sorin Group (4,500 employees) leads the international market for cardiac surgery devices and systems and is a top player in the European market for cardiac rhythm management devices.

MARKET CAP (AS OF JULY 11, 2007):€ 887 MILLION

Bloomberg: SRN.IM

Reuters: SORN.MI

OUR MISSION

- Create value by developing innovative and cost-effective therapies.
- Contribute to achieving a significant improvement in each patient's quality of life and well-being.
- Provide responsive support to physicians, hospitals and healthcare authorities in all situations related to the use of our technologies.
- Achieve business objectives which create shareholder value, while maintaining the highest standard of ethics in all of our global operating units.

STRATEGIC DIRECTION

Sorin's goal

From a key player in the cardiac surgery segment to a world leader of the cardiovascular market.

Vision and Strategy by Therapeutic Area

CS: Become a worldwide leader in Heart Valve Therapy by entering the US tissue valve market and investing in the development of new, less invasive, technologies. Expand our worldwide leadership and increase profitability in Perfusion and Blood Management systems through on-going new product/services launches and efficiencies.

CRM: Become the leader in Hemodynamic Management of Heart Failure by investing in Tachy and CRT growth, focusing on US expansion, profitability and cash-flow generation.

VT: Become a key European player through continuous innovation in coronary therapies through active and passive coating technologies, supported by a strong clinical science tradition and close partnerships with clients.


RC: Become a leading Renal Care supplier focused on innovative therapies while reinforcing our international presence.

REVENUE BREAKDOWN BY THERAPEUTIC AREA*

BY BUSINESS

- Cardiac Surgery
- Cardiac Rhythm Management
- Vascular Therapy
- Renal Care

* 2006 Revenue: € 791.7 million



PRODUCT PORTFOLIO UPDATES

March 2007

CE Mark approval and first implants of Sorin's next-generation REPLY™ pacemakers, the world's smallest dual-chamber devices (8cc).

December 2006

First implant in human of Sorin's uniquely-designed tissue heart valve suitable for percutaneous procedures.

July 2006

FDA approval of the new Stöckert heart-lung machine S5.

May 2006

FDA approval of OVATIO ICD.

HISTORY

Sorin was founded in 1956 in northern Italy to respond to the problem of nuclear energy production. The name Sorin, in fact, comes from the initials of "Società Ricerche Impianti Nucleari", meaning Company for Nuclear Plant Research. During the 1960s, the technological know-how already acquired in a wide range of scientific fields was refocused into the biomedical sector.

In the early 90's, Sorin acquired Dideco and Stöckert, two internationally-recognized producers of life-support systems used in cardiac surgery, and Bellco, a leading provider of haemodialysis products and services for the treatment of chronic renal failure. In 1999, Sorin purchased COBE Cardiovascular, a leading manufacturer of advanced cardiopulmonary and autologous blood processing products. In 2001, with the acquisition of ELA Medical, Sorin strengthened its position in the cardiac rhythm management field. The acquisitions in 2003 of CarboMedics, to complete its portfolio of mechanical valve products, and Mitroflow, producer of revolutionary aortic pericardial heart valves, have increased Sorin's position as a major provider of heart valve therapy.

In January 2004, Sorin Group was listed on the Italian Stock Exchange.

FINANCIAL HIGHLIGHTS

€ mln	2006	2006 vs 2005*
Revenues	791.7	+5.5%
EBITDA	85.8	+17.4%
EBIT	30.6	+79.4%
NET INCOME	3.4	n.m.

* On comparable FX rates

RESEARCH AND DEVELOPMENT

Technological research and development represent the driving force to preserve the Sorin Group's role as an industry leader in the field of cardiovascular diseases. Its internal R&D capabilities enable the Sorin Group to design, develop, engineer and manufacture systems and products that use cutting-edge technology to ensure patient safety. Sorin has over 450 people working in R&D centres in North America, France, Italy and Germany, and its IP portfolio consists of several hundreds of patents.

The Group's technological leadership is demonstrated by its product pipeline. Some examples include:

Heart Valve Therapy Area: the "Perceval" project, which involves the development of a stentless aortic valve prosthesis that can be used for implantation purposes and/or to replace diseased aortic valves through minimally invasive procedures that have a very low impact on patients.

Perfusion & Blood Management Area: the "APOPS" (Advanced Patient Oriented Perfusion System) project, Sorin's unique study to design a new automated and integrated ECC system aimed at providing superior clinical outcomes and improved patient safety, through new and improved technologies marketed individually.

Cardiac Rhythm Management Area: "SYNDELY", the program to develop the next generation of defibrillators, which will include a complete line of VR, DR and CRT-D devices characterized by a high energy release and left ventricular bipolar pacing capability. The CRT-D version of the platform will include a breakthrough development in the treatment of heart failure: the use of different sensors (for G acceleration, MV multiventilation and peak endocardial acceleration) in combination with innovative diagnosis and therapy algorithms, which will allow the illness to be treated hemodynamically, with automatic regulation of therapy delivery (AV and VV delay) and heart failure prediction.

Vascular Therapy Area: "Janus SRT" (Sustained Release of Tacrolimus) stent, the second generation of drug-eluting stents, for which in vitro experimental testing are continuing and in vivo experimental animal testing is under way.

This device is based on a new stent platform made of a chromium-cobalt alloy, which allows for a more flexible (dose modulation) and versatile (possibility of multiple drug-loading, i.e. anti-inflammatory and anti-proliferative effect) drug release.

FOR MORE INFORMATION PLEASE CONTACT:

Sorin Group

Via B. Crespi, 17 - 20159 Milan-Italy

Tel +39 02 69969 711

www.sorin.com

Jason M. Jacobs

Director, Communication & Media Relations

jason.jacobs@sorin.com

Tel +39 02 69969 722

Fax +39 02 69969 790

Marco Chiadò Piat

VP, Corporate Development

marco.chiadopiat@sorin.com

Tel +39 02 69969 741

Fax +39 02 69969 790